3H Health Investment

3H Health Investment is a private equity firm based in Hong Kong that specializes in the healthcare sector in China. The firm focuses on investing in various segments of the healthcare industry, including healthcare devices and diagnostics, healthcare services, pharmaceuticals, and healthcare products. With a proactive and innovative investment approach, 3H Health Investment leverages its deep understanding of the Chinese market and extensive industry connections to identify and create value in investment opportunities. The firm's expertise in fund management further enhances its ability to navigate the complexities of the healthcare landscape in China.

Sheng Li

Founding Managing Partner

Minchuan Wang

Founding Managing Partner

Shunlong Wang

Chairman and Founder

21 past transactions

Timberlyne Therapeutics

Series A in 2025
Timberlyne Therapeutics is a biopharmaceutical company focused on developing and commercializing innovative therapies for autoimmune diseases. It leverages its team's expertise in drug development to acquire promising assets targeting unmet medical needs. The company specializes in monoclonal antibodies with enhanced complement-dependent cytotoxicity, specifically targeting CD38, a protein highly expressed in various immune cells. This approach enables rapid and durable responses across a range of autoimmune diseases.

Angitia Biopharmaceuticals

Series C in 2024
Angitia Biopharmaceuticals is a global biotechnology company dedicated to the discovery and development of innovative therapeutics targeting serious musculoskeletal diseases. The company specializes in researching and developing breakthrough therapies for conditions affecting bones, muscles, and joints. By focusing on creating novel drugs, Angitia aims to provide effective treatments that enhance patient recovery from severe musculoskeletal ailments.

Angitia Biopharmaceuticals

Series B in 2023
Angitia Biopharmaceuticals is a global biotechnology company dedicated to the discovery and development of innovative therapeutics targeting serious musculoskeletal diseases. The company specializes in researching and developing breakthrough therapies for conditions affecting bones, muscles, and joints. By focusing on creating novel drugs, Angitia aims to provide effective treatments that enhance patient recovery from severe musculoskeletal ailments.

Chamlion

Series B in 2023
Chamlion provides end-to-end digital dentistry solutions based on 3D printing technology.

Chenglian Technology

Series B in 2023
Chamlion 3D is a national high-tech enterprise incubated and established by the Additive Manufacturing Institute of Nanjing University of Aeronautics and Astronautics. Digital solutions for dental 3D printing, leading the digital transformation and upgrading of the industry. Chenglian Technology is deeply engaged in the field of dentistry, with its in-depth understanding of the industry and rich product development.

Alebund Pharmaceuticals

Series C in 2023
Alebund Pharmaceuticals is a biopharmaceutical company specializing in the discovery and development of innovative therapies for renal diseases and associated chronic conditions. The company focuses on researching and commercializing treatments for a variety of kidney-related ailments, including chronic kidney disease, dialysis complications, nephropathy, diabetic kidney disease, and autosomal dominant polycystic kidney disease. With a diversified pipeline of drug candidates, Alebund Pharmaceuticals aims to deliver comprehensive, high-quality solutions to patients suffering from renal diseases, addressing both immediate and long-term healthcare needs in this critical area.

Yuanyin Bio

Series A in 2022
Yuanyin Bio is a biotechnology company focuses on the research and application of circular RNA technology in the field of innovative drugs and therapies, builds a robust pipeline of preventive and therapeutic new drugs, and is dedicated to addressing clinically unmet disease needs. They serve in the field of innovative drugs and therapies. It establishes a pipeline of preventive and therapeutic new drugs and is committed to solving clinically unmet disease needs.

Edge Medical Robotics

Series C in 2021
Edge Medical Robotics, Inc. is a Shenzhen, China-based company that specializes in the design and development of advanced surgical equipment. Founded on May 4, 2017, the company is dedicated to researching and promoting cutting-edge smart technologies aimed at enhancing surgical safety and treatment efficacy. By focusing on the pursuit of excellence and refinement in its products, Edge Medical Robotics seeks to elevate health standards and improve overall social health outcomes.

Tripod Preclinical Research

Venture Round in 2021
Tripod Preclinical Research is a Contract Research Organization that specializes in preclinical research services tailored for the biopharmaceutical industry. The company offers a comprehensive range of services, including nonhuman primate disease models, pharmacological efficacy assessments, early drug evaluations, and GLP toxicology. Tripod is committed to supporting global pharmaceutical companies, research and development enterprises, and medical device manufacturers in the evaluation of new chemical entities, food additives, biologics, pesticides, veterinary drugs, and cosmetics. Additionally, the organization provides technology support in areas such as translational medicine, clinical trials, biological analysis, and the management of biological sample banks, ensuring that its clients have the necessary resources to advance their research and development efforts effectively.

Vision X

Series B in 2021
Vision X is a solutions provider for medical equipment in the field of ophthalmology and optometry.

Alebund Pharmaceuticals

Series B in 2021
Alebund Pharmaceuticals is a biopharmaceutical company specializing in the discovery and development of innovative therapies for renal diseases and associated chronic conditions. The company focuses on researching and commercializing treatments for a variety of kidney-related ailments, including chronic kidney disease, dialysis complications, nephropathy, diabetic kidney disease, and autosomal dominant polycystic kidney disease. With a diversified pipeline of drug candidates, Alebund Pharmaceuticals aims to deliver comprehensive, high-quality solutions to patients suffering from renal diseases, addressing both immediate and long-term healthcare needs in this critical area.

Kanova

Series B in 2021
Kanova is a biopharmaceutical company dedicated to the development of therapeutic antibodies and innovative combination therapies, specifically targeting immuno-oncology and autoimmune diseases. The company offers a biomedical technology service platform that supports pharmaceutical research and production in the biotechnology sector. By providing antibody-based drugs that enhance immune system functionality, along with technical consultation and drug quality inspection services, Kanova enables its clients to improve drug quality and efficiently advance the field of biomedicine.

Reliable Med

Series A in 2021
Reliable Med is a medical device developer focused on creating and providing clinical mass spectrometry equipment for in vitro diagnostic (IVD) tests. The company addresses a significant need in the medical industry by offering high-end clinical mass spectrometry solutions and IVD detection kits. By enhancing diagnostic capabilities, Reliable Med aims to enable healthcare professionals to diagnose patients more efficiently and accurately.

EdiGene

Series B in 2021
EdiGene Inc. is a biotechnology company specializing in the development of genome editing technologies for therapeutic applications in cancer and various genetic diseases. Founded in 2015 and headquartered in Beijing, China, with additional offices in Guangzhou and Cambridge, Massachusetts, EdiGene focuses on both ex vivo and in vivo gene-editing therapies. The company has established proprietary platforms for editing hematopoietic stem cells and T cells, as well as an RNA base editing approach for in vivo applications. EdiGene's innovative methods enable targeted modifications of genetic information in human cells and facilitate high-throughput drug discovery through advanced screening techniques. By translating these technologies into novel therapeutics, EdiGene aims to improve the safety and efficacy of gene therapy, ultimately benefiting patients, the pharmaceutical industry, and the scientific research community.

MicroTech Medical

Series D in 2020
MicroTech Medical, founded in January 2011 in Hangzhou Future Technical City, is a company focused on the research, development, and manufacturing of innovative and affordable medical devices for diabetes care. The firm specializes in creating both treatment and monitoring devices aimed at improving diabetes management, primarily serving the Chinese market while also reaching international customers. With significant backing from Eli Lilly and Company, MicroTech Medical is dedicated to enhancing the quality of life for individuals living with diabetes through advanced technology solutions.

Hemu (China) Biological Engineering

Series B in 2020
Hemu (China) Biological Engineering is a Chinese blood vessel intervention medical equipment firm.

EdiGene

Series B in 2020
EdiGene Inc. is a biotechnology company specializing in the development of genome editing technologies for therapeutic applications in cancer and various genetic diseases. Founded in 2015 and headquartered in Beijing, China, with additional offices in Guangzhou and Cambridge, Massachusetts, EdiGene focuses on both ex vivo and in vivo gene-editing therapies. The company has established proprietary platforms for editing hematopoietic stem cells and T cells, as well as an RNA base editing approach for in vivo applications. EdiGene's innovative methods enable targeted modifications of genetic information in human cells and facilitate high-throughput drug discovery through advanced screening techniques. By translating these technologies into novel therapeutics, EdiGene aims to improve the safety and efficacy of gene therapy, ultimately benefiting patients, the pharmaceutical industry, and the scientific research community.

Edge Medical Robotics

Series B in 2020
Edge Medical Robotics, Inc. is a Shenzhen, China-based company that specializes in the design and development of advanced surgical equipment. Founded on May 4, 2017, the company is dedicated to researching and promoting cutting-edge smart technologies aimed at enhancing surgical safety and treatment efficacy. By focusing on the pursuit of excellence and refinement in its products, Edge Medical Robotics seeks to elevate health standards and improve overall social health outcomes.

Shenqi Medical

Series C in 2020
Shenqi Medical specializes in the research and manufacturing of innovative medical devices, primarily targeting the Chinese market. The company offers a diverse product portfolio that includes solutions for cardiovascular issues, structural heart diseases, and both peripheral and neurovascular medical devices. Additionally, Shenqi Medical is dedicated to developing minimally invasive surgical products, which enhance the safety and reliability of cardiovascular surgeries. Through its focus on advanced medical technology, Shenqi Medical aims to improve patient outcomes and contribute to the evolving landscape of healthcare.

Citrine Medicine

Series A in 2020
Citrine Medicine is a rare disease-focused pharmaceutical firm.

MicroPort CardioFlow

Private Equity Round in 2020
Shanghai MicroPort CardioFlow Medtech Co., Ltd., established in 2015, is a medical device company specializing in advanced minimally invasive therapies for structural heart diseases. As a subsidiary of MicroPort Scientific Corporation, it focuses on the research, development, and commercialization of innovative solutions for valvular heart diseases. The company's product portfolio includes VitaFlow, VitaFlow Liberty, Alwide Plus, and a range of transcatheter aortic valve implantation (TAVI), transcatheter mitral valve (TMV), and surgical valve products, along with procedural accessories. Primarily operating in China, MicroPort CardioFlow emphasizes the importance of improving patient quality of life through reliable and affordable healthcare solutions while maintaining a global vision for its products and services.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.